73/100BGSK executives and insider trading
Luke V. Miels reported no open-market purchases or sales over the last twelve months.
Over the last twelve months GSK's insiders sold 0 shares for 0 USD in 0 sales on the open market, and bought 0 shares in 0 purchases.
Insiders over the last twelve months
- Insider sales
- 0
- Shares sold
- —
- Value sold
- —
- Insider purchasesWhat is insider trading? Insider trading here means the legal trades that a company's executives, directors and large owners make in its shares, reported to the SEC on Form 4.
- 0
Insiders buying against sellingWhat is a Rule 10b5-1 trading plan? A Rule 10b5-1 plan lets an insider fix future trades in advance, while holding no inside information, so later trades follow the plan, not a new decision.
Open-market purchases and sales reported on Form 4, by value. Awards, option exercises and shares withheld for tax are not counted. Whether a sale was under a Rule 10b5-1 plan is read from each Form 4 at the SEC (the box exists on filings since April 2023).
Executives and directors
The people who run the company and the directors who reported trades, with what each bought and sold on the open market over the last twelve months. The CEO first, then whoever traded most.
| Name | Position | Age | Shares sold (12 months) | Value sold (12 months) | Shares bought (12 months) | Last sale | Shares held after |
|---|---|---|---|---|---|---|---|
| Luke V. Miels CEO | Chief Executive Officer & Director | 52 | — | — | — | — | — |
| Constantin Fest | Senior Vice President & Head of Investor Relations | 49 | — | — | — | — | — |
| Jeff McLaughlin | VP of Investor Relations & Interim Head of Investor Relations | — | — | — | — | — | — |
| Philip C. Thomson | President of Global Affairs | — | — | — | — | — | — |
| Regis Simard | President of Global Supply Chain | — | — | — | — | — | — |
| Shobie Ramakrishnan | Chief Digital & Technology Officer | 55 | — | — | — | — | — |
| David Simon Redfern | President of Corporate Development | 60 | — | — | — | — | — |
| James Ford | Senior Vice President & Group General Counsel of Legal & Compliance | — | — | — | — | — | — |
| Tony Wood | Chief Scientific Officer and Head of R&D | — | — | — | — | — | — |
| Jesse L. Goodman | Scientific & Medical Expert | 75 | — | — | — | — | — |
| Emma Natasha Walmsley | Executive Officer | 57 | — | — | — | — | — |
| Julie Brown | Chief Financial Officer & Executive Director | 64 | — | — | — | — | — |
| Roanne Parry | Chief People Officer | 52 | — | — | — | — | — |
Every insider transactionWhat is insider trading? Insider trading here means the legal trades that a company's executives, directors and large owners make in its shares, reported to the SEC on Form 4.
Insiders must report every trade in the company's shares to the SEC within two business days, on Form 4. Only purchases and sales are trades on the open market; awards, option exercises, shares withheld for tax and gifts come with pay, and the twelve-month totals leave them out.
| Date | Name | Transaction | Shares | Price | Value | Shares held after | Filing |
|---|
Common questions about GSK's executives and insiders
Source: Financial Modeling Prep